Abstract:Cellular interactions with extracellular matrix play essential roles in tumor initiation, progression and metastasis. Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase identified as a key mediator of signaling by integrins, a major family of cell surface receptors for extracellular matrix, as well as other receptors in both normal and cancer cells. FAK is activated by integrins through disruption of an auto-inhibitory intra-molecular interaction between its kinase domain and the amino terminal FERM domain. The activated FAK forms a binary complex with Src family kinases which can phosphorylate other substrates and trigger multiple intracellular signaling pathways to regulate various cellular functions. Subcellular localization of FAK in focal adhesions is essential for FAK signaling, which is another distinguishing feature of the kinase. Integrin-FAK signaling has been shown to activate a number of signaling pathways through phosphorylation and protein-protein interactions to promote tumorigenesis. FAK also plays a prominent role in tumor progression and metastasis through its regulation of both cancer cells and their microenvironments including cancer cell migration, invasion, epithelial to mesenchymal transition, and angiogenesis. More recently, a role for FAK in tumor initiation and progression has been demonstrated directly using xenograft as well as conditional knockout mouse models. In agreement with these experimental data, overexpression and activation of FAK have been found in a variety of human cancers. A number of small molecule inhibitors for FAK have been developed and in various phases of testing for cancer treatments. Overall, the intensive research on FAK signaling in cancer have yielded a wealth of information on this pivotal kinase and these and future studies are leading to potentially novel therapies for cancer.

Focal adhesion kinase-mediated interaction between tumor and immune cells in the tumor microenvironment: implications for cancer-associated therapies and tumor progression

Advances in the treatment of tumors with focal adhesion kinase inhibitors

Focal adhesion kinase: from biological functions to therapeutic strategies

Targeting FAK in anticancer combination therapies

Focal adhesion kinase signaling - tumor vulnerabilities and clinical opportunities

Signal transduction by focal adhesion kinase in cancer

Functional and clinical characteristics of focal adhesion kinases in cancer progression.

Focal adhesion kinase,a novel target for cancer therapy

Focal adhesion kinase inhibitors, a heavy punch to cancer

Focal adhesion kinase as a new player in the biology of onco-hematological diseases: the starting evidence

Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders

Advances in the activation of focal adhesion kinase and tumor progression

FAK expression regulation and therapeutic potential

Advance in focal adhesion kinase,a new antitumor drug target

Potential Focal Adhesion Kinase Inhibitors in Management of Cancer: Therapeutic Opportunities from Herbal Medicine

Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment

Focal Adhesion Kinase:Implications with Oncogenesis,Tumor Development and Prognosis

Development of Novel Focal Adhesion Kinase (FAK) Inhibitors for Targeting Cancer: Structural Insights and Therapeutic Potential

Targeting a key FAK-tor: the therapeutic potential of combining focal adhesion kinase (FAK) inhibitors and chemotherapy for chemoresistant non-small cell lung cancer

The Crosstalk between FAK and Wnt Signaling Pathways in Cancer and Its Therapeutic Implication

The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review